Labelling and packaging of medicinal products for human use following agreement of the Windsor Framework

AI Summary

This guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) outlines the implementation of labelling and packaging requirements under the Windsor Framework. The framework establishes a unified regulatory system where the MHRA serves as the sole authority for licensing human medicines across the entire United Kingdom, including Northern Ireland. A central requirement is the use of standardized packaging and labelling across all UK territories, effectively ending the need for separate versions for different regions. Significantly, the guidance confirms the disapplication of the European Union Falsified Medicines Directive (FMD) for products supplied to Northern Ireland. As this document is a general policy guidance, it does not specify individual company names, inspection dates, or violations. The regulatory framework focuses on transitioning away from EU-mandated safety features to a single UK-wide standard. Required actions for pharmaceutical companies include updating their supply chain and packaging protocols to ensure compliance with these new MHRA-led rules. This measure is designed to simplify distribution and guarantee that medicines remain available throughout the UK by removing regulatory barriers previously imposed by the protocol. All affected manufacturers must now align their production to these consolidated UK requirements to ensure uninterrupted market access.